Assignee
RICHTER GEDEON NYRT
HU·37 granted patents·26 pending applications·109 citations·filing 2005–2024
Top patents by PatentIndex Score
63 records- 0194US8361995B2Drug comprising at least one gestagenRICHTER GEDEON NYRT·Filed 2009·Granted Jan 29, 2013·52 cites·21 claims
- 0291USRE47350EPharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2017·Granted Apr 16, 2019·4 cites·10 claims
- 0391USRE47333EPharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2017·Granted Apr 2, 2019·4 cites·10 claims
- 0488US9056846B2Pharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2012·Granted Jun 16, 2015·4 cites·10 claims
- 0588US7943621B2Salts of piperazine compounds as D3/D2 antagonistsRICHTER GEDEON NYRT·Filed 2008·Granted May 17, 2011·17 cites·17 claims
- 0688US7875610B2Pyrimidinyl-piperazines useful as D3/D2 receptor ligandsRICHTER GEDEON NYRT·Filed 2008·Granted Jan 25, 2011·14 cites·9 claims
- 0785USRE49110EPharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2019·Granted Jun 21, 2022·1 cites·11 claims
- 0876US8034827B2Phenanthridine derivatives as bradykinin antagonistsRICHTER GEDEON NYRT·Filed 2006·Granted Oct 11, 2011·7 cites·7 claims
- 0974USRE49302EPharmaceutical formulations containing dopamine receptor ligandsRICHTER GEDEON NYRT·Filed 2019·Granted Nov 15, 2022·0 cites·15 claims
- 1073US12168007B1Substituted piperazines as dopamine D3/D2 receptor modulatorsRICHTER GEDEON NYRT·Filed 2024·Granted Dec 17, 2024·0 cites·3 claims
- 1169US10487138B2Immunoglobulin purification using pre-cleaning stepsRICHTER GEDEON NYRT·Filed 2015·Granted Nov 26, 2019·3 cites·5 claims
- 1267US2025049786A1Dopamine d3/d2 receptor modulating compoundsRICHTER GEDEON NYRT·Filed 2024·Application pending·0 cites
- 1366US9994525B2H3 antagonists containing phenoxypiperidine core structureRICHTER GEDEON NYRT·Filed 2014·Granted Jun 12, 2018·2 cites·16 claims
- 1466US2026027109A1Orally disintegrating pharmaceutical tablet containing cariprazineRICHTER GEDEON NYRT·Filed 2023·Application pending·0 cites
- 1564US2022016244A1Pharmaceutical anti-tnf-alpha antibody formulationRICHTER GEDEON NYRT·Filed 2021·Application pending·0 cites
- 1663US2025064823A1Thiadiazine derivativesRICHTER GEDEON NYRT·Filed 2024·Application pending·0 cites
- 1762US11298363B2Triazolobenzazepines as vasopressin V1a receptor antagonistsRICHTER GEDEON NYRT·Filed 2018·Granted Apr 12, 2022·1 cites·21 claims
- 1861US2011190347A1Methods for treating neuropathic painRICHTER GEDEON NYRT·Filed 2009·Application pending·0 cites
- 1952US2023181572A1Carbamoyl cyclohexane derivatives for treating autism spectrum disorderRICHTER GEDEON NYRT·Filed 2022·Application pending·0 cites
- 2051US12194050B2Thiadiazine derivativesRICHTER GEDEON NYRT·Filed 2019·Granted Jan 14, 2025·0 cites·15 claims
- 2151US9562067B2Process for the production of 19-norpregn-4-en-3,20-dione-17α-ol(gestonorone) and intermediates thereforRICHTER GEDEON NYRT·Filed 2014·Granted Feb 7, 2017·0 cites·20 claims
- 2251US2025122542A1Process to produce (1r,4r)-4-substituted cyclohexane-1-aminesRICHTER GEDEON NYRT·Filed 2022·Application pending·0 cites
- 2351US2025011382A1Method for the manufacture of biopharmaceuticalsRICHTER GEDEON NYRT·Filed 2024·Application pending·0 cites
- 2450US12433948B2Aqueous pharmaceutical formulationsRICHTER GEDEON NYRT·Filed 2019·Granted Oct 7, 2025·0 cites·12 claims
- 2550US11547707B2Carbamoyl cyclohexane derivatives for treating autism spectrum disorderRICHTER GEDEON NYRT·Filed 2020·Granted Jan 10, 2023·0 cites·15 claims
- 2650US2020222391A1Solid preparation of cariprazine for oral administrationRICHTER GEDEON NYRT·Filed 2018·Application pending·0 cites
- 2749US10660789B21,4-dihydropyridine derivatives with HSP modulating activityRICHTER GEDEON NYRT·Filed 2019·Granted May 26, 2020·0 cites·18 claims
- 2849US2022372157A1Method for increasing the galactose content of recombinant proteinsRICHTER GEDEON NYRT·Filed 2022·Application pending·0 cites
- 2947US12473293B2Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivativesRICHTER GEDEON NYRT·Filed 2021·Granted Nov 18, 2025·0 cites·19 claims
- 3047US11427639B2Antibody-containing aqueous formulation and use thereofRICHTER GEDEON NYRT·Filed 2019·Granted Aug 30, 2022·0 cites·12 claims
- 3147US11274119B2Industrial process for the synthesis of nomegestrol-acetateRICHTER GEDEON NYRT·Filed 2017·Granted Mar 15, 2022·0 cites·7 claims
- 3247US2025051323A1BICYCLIC AMINE DERIVATIVES AS GABAA alpha5 RECEPTOR MODULATORSRICHTER GEDEON NYRT·Filed 2022·Application pending·0 cites
- 3347US2022235030A1Selective histamine h3 antagonist acid addition salts and process for the preparation thereofRICHTER GEDEON NYRT·Filed 2020·Application pending·0 cites
- 3446US10258498B21,4-dihydropyridine derivatives with Hsp modulating activityRICHTER GEDEON NYRT·Filed 2012·Granted Apr 16, 2019·0 cites·20 claims
- 3546US8367394B2Process for the synthesis of 9α-hydroxy-steroidsRICHTER GEDEON NYRT·Filed 2008·Granted Feb 5, 2013·0 cites·7 claims
- 3644US2017252437A1Pharmaceutical anti-tnf-alpha antibody formulationRICHTER GEDEON NYRT·Filed 2015·Application pending·0 cites
- 3744US2022235034A1Selective histamine h3 receptor antagonists for treating autism spectrum disorderRICHTER GEDEON NYRT·Filed 2020·Application pending·0 cites
- 3843US2011002993A1Film coated tablets containing drospirenone as active agent and a method for the preparation thereofRICHTER GEDEON NYRT·Filed 2008·Application pending·0 cites
- 3942US11026946B2Pharmacologically active alicyclic-substituted pyrazolo[1,5-a]pyrimidine derivativesRICHTER GEDEON NYRT·Filed 2018·Granted Jun 8, 2021·0 cites·24 claims
- 4042US9676814B2Industrial process for the synthesis of ulipristal acetate and its 4′-acetyl analogueRICHTER GEDEON NYRT·Filed 2014·Granted Jun 13, 2017·0 cites·20 claims
- 4142US2015284338A1Industrial process for the synthesis of pyrimidinyl-piperazine derivativesRICHTER GEDEON NYRT·Filed 2013·Application pending·0 cites
- 4241US12540160B2Methods for the purification of refolded Fc-peptide fusion proteinRICHTER GEDEON NYRT·Filed 2021·Granted Feb 3, 2026·0 cites·25 claims
- 4341US12168791B2Method for modifying the glycosylation profile of a recombinant glycoprotein produced in cell cultureRICHTER GEDEON NYRT·Filed 2019·Granted Dec 17, 2024·0 cites·21 claims
- 4441US9683010B2Process for the production of 21-methoxy-11-beta-phenyl-19-nor-pregna-4,9-diene-3,20-dione derivativesRICHTER GEDEON NYRT·Filed 2015·Granted Jun 20, 2017·0 cites·9 claims
- 4541US2024067637A1NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORSRICHTER GEDEON NYRT·Filed 2021·Application pending·0 cites
- 4640US12370182B2Bicyclic derivatives as GABAA A5 receptor modulatorsRICHTER GEDEON NYRT·Filed 2019·Granted Jul 29, 2025·0 cites·19 claims
- 4740US9416164B2Method for the production of polypeptidesRICHTER GEDEON NYRT·Filed 2013·Granted Aug 16, 2016·0 cites·24 claims
- 4840US2021330650A1Spirochromane derivativesRICHTER GEDEON NYRT·Filed 2019·Application pending·0 cites
- 4940US2024043418A11,3-dihydro-2h-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulatorsRICHTER GEDEON NYRT·Filed 2021·Application pending·0 cites
- 5039US2014316007A1Therapeutic combination of memantine and baclofen and pharmaceutical composition containing themRICHTER GEDEON NYRT·Filed 2012·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when RICHTER GEDEON NYRT files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →